Today, millions of women are surviving breast cancer. It is a malignant tumor that starts in the cells of the breast.聽It聽can grow into (invade) surrounding tissues or spread (metastasize) to distant areas of the body. No one exactly knows why some women get breast cancer; there are a...
Tamoxifen therapy has managed to reduce the chances of a breast cancer survivor developing the cancer again by 50%. However, this anti-estrogen medication does not always bring down estrogen levels enough. Rock explained in a telephone interview with Reuters that a patient cannot just assume that...
We assess the issue in clinically relevant settings by a genetic approach and inject ER + breast cancer cell lines and patient-derived tumor cells to the milk ducts of immunocompromised mice. Such ER + xenografts were exposed to physiologically relevant levels of 17-β-estradiol (E2) ...
In a human-in-mouse model of ER+/HER2+ breast cancer, adjuvant paclitaxel plus trastuzumab ± pertuzumab for 4 weeks, followed by “extended adjuvant therapy” with fulvestrant plus neratinib for an additional 4 weeks, was associated with maintenance of a complete response (CR), whereas ...
Breast cancer ranks no. 1 in women cancer worldwide, while 60–70% are estrogen receptor alpha positive. The estrogen selective modulators, such as tamoxifen, become the effective drugs for controlling ER alpha breast cancer progression. However, tamoxif
An anti-estrogen drug has shown a "promising" 65-percent reduction of breast cancer risk among post-menopausal women, according to the findings of a study released Saturday. The research could lead to a breakthrough for women who are at increased risk of developingbreast cancer, which strikes ...
Breast cancer, stem/progenitor cells and the estrogen receptor Dontu G,El-Ashry D,Wicha MS.Breast cancer,stem/progenitor cells and the estrogen receptor[J].Trends Endocrinol Metab,2004,15(5):193-197... Gabriela,Dontu,and,... - 《Trends in Endocrinology & Metabolism》 被引量: 643发表: ...
Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk[J]. Epidemiol Rev,1993,15(1):17-20. . 3. 杨才明, 夏淑君.HER2 2/neu基因蛋白、BRCA1和BRCA2基因突变检测在乳腺癌诊断和治疗中的临床意义[J].标记免疫分析与临床,2005,12(1):43-45. . 4. WILEY S R, SCHOOL...
Objective.—To provide an overview of the postmenopausal estrogen/breast cancer controversy emphasizing the sources of disagreement in the literature and
Espeland, PhD; Jean Wactawski-Wende, PhD; for the WHI Investigators JAMA Comment & Response Menopausal Estrogen Therapy and Breast Cancer Mortality Martha Hickey, MD, MBChB, MSc, FRCOG, FRANZCOG; Helen C. McNamara, MBBS, BMedSci; Gita D. Mishra, PhD, CStat, CSci JAMA ...